LENZ Therapeutics, Inc. 8-K

What Happened

• LENZ Therapeutics, Inc. announced its financial results for the quarter ended March 31, 2026 and furnished a press release on May 11, 2026. The company reported this disclosure on Form 8‑K under Item 2.02 (Results of Operations and Financial Condition). The press release is attached as Exhibit 99.1 and was signed on the filing by Daniel Chevallard, Chief Financial Officer.

Key Details

• Filing date: May 11, 2026 (Form 8‑K).
• Quarter covered: Quarter ended March 31, 2026 (Q1 2026).
• Disclosure format: Press release attached as Exhibit 99.1 and incorporated by reference.
• Authorized signatory: Daniel Chevallard, CFO (Principal Financial and Accounting Officer).
• Interactive XBRL cover page data provided (Exhibit 104).

Why It Matters

• This 8‑K is the company’s official, timely disclosure of its recent quarterly results (earnings, revenue and other financial metrics are expected in the press release). Retail investors should read the attached press release for the specific numbers and any management commentary, and watch for the company’s upcoming 10‑Q for full financial statements and details. This filing does not report any other material events (such as executive changes, mergers or bankruptcies).